The Course of COVID-19 in a Patient with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Clone: A Case Report and Literature Review

Introduction: Aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are bone marrow failure syndromes. A 20–40% of patients with AA have a PNH clone at diagnosis. To date, there are little data about the course of COVID-19 in patients with AA and PNH. Case Presentation: A 36-year-old gentleman, who was previously diagnosed as a case of AA with PNH clones off immune-suppressive therapy, presented with fever and cough and was diagnosed with mild pneumonia due to COVID-19 with positive nasopharyngeal swab polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2. His clinical course was benign except transient thrombocytopenia. He was asymptomatic after day 4, and viral PCR was negative on day 21. Discussion: Though studies have shown that COVID-19 is associated with lymphopenia, our patient had a normal to high lymphocyte count. The neutrophil to lymphocyte ratio (NLR) was <1 during COVID-19, which correlates with the mild course of the disease. To know whether elevated lymphocyte count, low NLR, and benign course of COVID-19 is a standard feature for all patients with underlying AA, we need more case reports and series. The significance of this case report is that it describes the course of COVID-19 in a patient with AA and PNH clones and, up to our knowledge, is the first report showcasing the association between these rare combinations of diseases.

[1]  M. Yassin,et al.  A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency , 2020, The American journal of case reports.

[2]  M. Loeb,et al.  Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  S. Montoto,et al.  The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. , 2020, Bone marrow transplantation.

[4]  S. Montoto,et al.  The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy , 2020, Bone Marrow Transplantation.

[5]  H. Bai,et al.  [A case report of aplastic anemia accompanied with COVID-19]. , 2020 .

[6]  Jian-Ping Liu,et al.  The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients , 2020, International Immunopharmacology.

[7]  A. Cope,et al.  Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence , 2020, Ecancermedicalscience.

[8]  A. Bacigalupo How I treat acquired aplastic anemia. , 2017, Blood.

[9]  G. Papanicolaou,et al.  Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Cappellini Coagulation in the pathophysiology of hemolytic anemias. , 2007, Hematology. American Society of Hematology. Education Program.

[11]  Neal Young,et al.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[12]  N. Young Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. , 2000, Seminars in hematology.

[13]  N. Young The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. , 1992, Blood.